Vantomme V - Search Results

1

Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin.

Lee RS, Tartour E, van der Bruggen P, Vantomme V, Joyeux I, Goud B, Fridman WH, Johannes L. Lee RS, et al. Among authors: vantomme v. Eur J Immunol. 1998 Sep;28(9):2726-37. doi: 10.1002/(SICI)1521-4141(199809)28:09<2726::AID-IMMU2726>3.0.CO;2-W. Eur J Immunol. 1998. PMID: 9754560 Free article.

2

Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer.

Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P. Chaux P, et al. Among authors: vantomme v. Int J Cancer. 1998 Aug 12;77(4):538-42. doi: 10.1002/(sici)1097-0215(19980812)77:4<538::aid-ijc11>3.0.co;2-2. Int J Cancer. 1998. PMID: 9679755

3

Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.

Chaux P, Luiten R, Demotte N, Vantomme V, Stroobant V, Traversari C, Russo V, Schultz E, Cornelis GR, Boon T, van der Bruggen P. Chaux P, et al. Among authors: vantomme v. J Immunol. 1999 Sep 1;163(5):2928-36. J Immunol. 1999. PMID: 10453041

4

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes.

Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P. Chaux P, et al. Among authors: vantomme v. J Exp Med. 1999 Mar 1;189(5):767-78. doi: 10.1084/jem.189.5.767. J Exp Med. 1999. PMID: 10049940 Free PMC article.

5

A new tumor-specific antigenic peptide encoded by MAGE-6 is presented to cytolytic T lymphocytes by HLA-Cw16.

Vantomme V, Boël P, De Plaen E, Boon T, van der Bruggen P. Vantomme V, et al. Cancer Immun. 2003 Dec 10;3:17. Cancer Immun. 2003. PMID: 14664500

6

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

Jacquemin M, Vantomme V, Buhot C, Lavend'homme R, Burny W, Demotte N, Chaux P, Peerlinck K, Vermylen J, Maillere B, van der Bruggen P, Saint-Remy JM. Jacquemin M, et al. Among authors: vantomme v. Blood. 2003 Feb 15;101(4):1351-8. doi: 10.1182/blood-2002-05-1369. Epub 2002 Oct 17. Blood. 2003. PMID: 12393451 Free article.

7

Characterization of the GAGE genes that are expressed in various human cancers and in normal testis.

De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P. De Backer O, et al. Among authors: vantomme v. Cancer Res. 1999 Jul 1;59(13):3157-65. Cancer Res. 1999. PMID: 10397259

8

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma.

Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ. Gaugler B, et al. Among authors: vantomme v. Immunogenetics. 1996;44(5):323-30. doi: 10.1007/BF02602776. Immunogenetics. 1996. PMID: 8781117

9

Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.

Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Guéguen M. Vantomme V, et al. J Immunother. 2004 Mar-Apr;27(2):124-35. doi: 10.1097/00002371-200403000-00006. J Immunother. 2004. PMID: 14770084 Clinical Trial.

10

Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.

Folschweiller N, Vanden Abeele C, Chu L, Van Damme P, García-Sastre A, Krammer F, Nachbagauer R, Palese P, Solórzano A, Bi D, David MP, Friel D, Innis BL, Koch J, Mallett CP, Rouxel RN, Salaun B, Vantomme V, Verheust C, Struyf F. Folschweiller N, et al. Among authors: vantomme v. Lancet Infect Dis. 2022 Jul;22(7):1062-1075. doi: 10.1016/S1473-3099(22)00024-X. Epub 2022 Apr 21. Lancet Infect Dis. 2022. PMID: 35461522 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters